The effect of metformin on the metabolic abnormalities associated with upper-body fat distribution

Diabetes Care

Volumn 19, Issue 9, 1996, Pages 920-926

  Fontbonne, Annick ^a   Charles, M Aline ^a   Juhan Vague, Irene ^b   Bard, Jean Marie ^a   André, Philippe ^d   Isnard, Françoise ^d   Cohen, Jean Marie ^a   Grandmottet, Pierre ^c   Vague, Philippe ^b   Safar, Michel E ^a,c   Eschwège, Eveline ^a  

^a INSERM   (France)

^b TIMONE HOSPITAL   (France)

^c LIPHA Company   (France)

^d Open Rome   (France)

Author keywords

[No Author keywords available]

Indexed keywords

CHOLESTEROL; GLUCOSE; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; INSULIN; LOW DENSITY LIPOPROTEIN CHOLESTEROL; METFORMIN; TISSUE PLASMINOGEN ACTIVATOR; TRIACYLGLYCEROL;

ADULT; AGED; ARTICLE; CARDIOVASCULAR DISEASE; CHOLESTEROL BLOOD LEVEL; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DIABETES MELLITUS; DIARRHEA; DOUBLE BLIND PROCEDURE; FEMALE; GLUCOSE BLOOD LEVEL; HUMAN; INSULIN BLOOD LEVEL; INSULIN RESISTANCE; MAJOR CLINICAL STUDY; MALE; METABOLIC DISORDER; MULTICENTER STUDY; OBESITY; ORAL DRUG ADMINISTRATION; PRIMARY PREVENTION; RANDOMIZED CONTROLLED TRIAL; WEIGHT REDUCTION;

EID: 9544247850     PISSN: 01495992     EISSN: None     Source Type: Journal    
DOI: 10.2337/diacare.19.9.920     Document Type: Article

References (34)

1. Reaven GM: Role of insulin resistance in human disease. Diabetes 37:1595-1607, 1988
2. Björntorp P: "Portal" adipose tissue as a generator of risk factors for cardiovascular disease and diabetes. Arteriosclerosis 10: 493-496, 1990
3. Kissebah AH: Insulin resistance in visceral obesity. Int J Obesity 15:109-115, 1991
4. Kaplan NM: The deadly quartet: upper-body obesity, glucose intolerance, hypertriglyceridemia, and hypertension. Arch Intern Med 149:1514-1520, 1989
5. Foster DW: Insulin resistance: a secret killer? N Engl J Med 320:733-734, 1989
6. Juhan-Vague I, Alessi MC, Vague P: Increased plasma plasminogen activator inhibitor 1 levels: a possible link between insulin resistance and atherothrombosis. Diabetologia 34:457-462, 1991
7. Austin MA: Plasma triglyceride and coronary heart disease. Arteriosder Thromb 11: 2-14, 1991
8. Gordon T, Castelli WP, Hjortland MC, Kannel WB, Dawber TR: High density lipoprotein as a protective factor against coronary heart disease. Am J Med 62:707-714, 1977
9. Hamsten A, De Faire U, Walldius G, Dahlen G, Szamosi A, Landou C, Blombäck M, Wiman B: Plasminogen activator inhibitor in plasma: risk factor for recurrent myocardial infarction. Lancet ii:3-9, 1987
10. Bailey CJ, Turner RC: Metformin. N Engl J Med 334:574-579, 1996
11. République Française: Ministère de la solidarité, de la santé et de la protection sociale: protection of persons undergoing biomedical research. In Acts of Parliament. Paris, Journal Official de la République Francaise, 1990
12. WHO Study Group: Diabetes Mellitus. Geneva, World Health Org., 1985 (Tech. Rep. Ser., no. 727), p. 9-15
13. Campbell IW: Sulfonylureas and metformin: efficacy and inadequacy. In New Antidiabetic Drugs. Bailey CJ, Flatt PR, Eds. London, Smith-Gordon, 1990, p. 33-51
14. Lindgarde E: Coupling between dietary changes, reduced body weight, muscle fiber size and improved glucose tolerance in middle-aged men with impaired glucose tolerance. Acta Med Scand 212:99-106, 1982
15. Ericksson E, Ranby M, Gyzander E, Risberg B: Determination of plasminogen activator inhibitor in plasma using t-PA and a chromogenic single-point poly-D-lysine stimulated assay. Thromb Res 50:91-101, 1988
16. Declerck PJ, Alessi MC, Verstreken M, Kruithof EKO, Juhan-Vague I, Collen D: Measurement of plasminogen activator inhibitor 1 in biological fluids with a murine monoclonal antibody based enzyme linked immunosorbent assay. Blood 71:220-225, 1988
17. Holvoet P, Cleemput H, Collen D: Assay of human tissue type plasminogen activator (t-PA) with an enzyme linked immunosorbent assay (ELISA) based on three murine monoclonal antibodies to t-PA. Thromb Haemostas 54:684-687, 1985
18. Jackson RA, Hawa MI, Jaspan JB, Sim BM, Di Silvio M, Fearherbe D: Mechanism of metformin action in non-insulin-dependent diabetes. Diabetes 36:632-640, 1987
19. Lalor BC, Bhatnagar D, Winocour PH, Ishola M, Arrol S, Brading M, Darrington PN: Placebo controlled trial of the effects of guar gum and metformin on fasting blood glucose and serum lipids in obese, type 2 diabetic patients. Diabetic Med 7:242-245, 1990
20. United Kingdom Prospective Diabetes Study Group: United Kingdom Prospective Diabetes Study (UKPDS) 13: relative efficacy of randomly allocated diet, sulphonylurea, insulin, or metformin in patients with newly-diagnosed non-insulin dependent diabetes followed for three years. Br Med J 310:83-88, 1995
21. Vague P, Juhan-Vague I, Alessi MC, Badier C, Valadier J: Metformin decreases the high plasminogen activator inhibition capacity, plasma insulin and triglyceride levels in non-diabetic obese subjects. Thromb Haemost 57:326-328, 1987
22. Giugliano D, De Rosa N, Di Maro G, Monfella R, Acampera R, Buoninconti R, D'Onfrio F: Metformin improves glucose, lipid metabolism, and reduces blood pressure in hypertensive, obese women. Diabetes Care 16:1387-1390, 1993
23. Hother-Nielsen O, Schmitz O, Andersen PH, Beck-Nielsen H, Pedersen O: Metformin improves peripheral but not hepatic insulin action in obese patients with type 11 diabetes. Acta Endocrinol 120:257-265, 1989
24. Wu MS, Johnston P, Sheu WHH, Hollenbeck CB, Jeng CY, Goldfine ID, Chen Y-DI, Reaven GM: Effect of metformin on carbohydrate and lipoprotein metabolism in NIDDM patients. Diabetes Care 13:1-8, 1990
25. Widen EIM, Eriksson JG, Groop LC: Metformin normalizes nonoxidative glucose metabolism in insulin-resistant normoglycemic first-degree relatives of patients with NIDDM. Diabetes 41:354-358, 1992
26. Alessi MC, Juhan-Vague I, Declerck JP, Collen D: Molecular forms of plasminogen activator inhibitor 1 (PAI 1) and tissue-type plasminogen activator (t-PA) in human plasma. Thumb Res 62:275-285, 1991
27. Landin K, Tengborg L, Smith U: Metformin and metoprolol CR treatment in non-obese men. J Int Med 235:335-341, 1994
28. Nagi DK, Yudkin JS: Effects of metformin on insulin resistance, risk factors for cardiovascular disease, and plasminogen activator inhibitor in NIDDM subjects. Diabetes Care 16:621-628, 1993
29. Ridker PM, Vaughan DE, Stampfer MJ, Manson JE, Hennekens CH: Endogenous tissue plasminogen activator and risk of myocardial infarction. Lancet 341:1165-1168, 1993
30. Taylor KG, John WG, Matthews KA, Wright AD: A prospective study of the effect of 12 months treatment on serum lipids and apolipoproteins A-1 and B in type 11 (non-insulin-dependent) diabetes. Diabetologia 23:507-510, 1982
31. Carlsen SM, Rossvoll O, Bjerve KS, Folling I: Metformin improves blood lipid pattern in nondiabetic patients with coronary heart disease. J Intern Med 239:227-233, 1996
32. Schneider J: Effects of metformin on dyslipoproteinemia in non-insulin-dependent diabetes mellitus. Diabete Metab 17: 185-190, 1991
33. Steiner G, Vranic M: Hyperinsulinemia and hypertriglyceridemia: a vicious cycle with atherogenic potential. Intern J Obes 6 (Suppl. 1):117-124, 1982
34. Pentikâinen PJ, Voutilainen E, Aro A, Uusitupa M, Penttilä I, Vapaatalo H: Cholesterol lowering effect of metformin in combined hyperlipidemia: placebo controlled double blind trial. Ann Med 22:307-312, 1990